Skip to content
Dx

HCPCS Level II · Temporary national codes (non-Medicare)

S9562Home injectable therapy, palivizumab or other monoclonal antibody for rsv, including administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem

✓ Active

Source: CMS HCPCS quarterly update, October 2026. Page updated September 29, 2026.

About S9562

S9562 is an HCPCS Level II code in the S series (temporary national codes (non-Medicare)), describing home injectable therapy, palivizumab or other monoclonal antibody for rsv, including administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem.

It was added to HCPCS effective 01/01/2003, and its current record took effect 04/01/2023.

Its Medicare coverage code is "I", meaning it is not payable by Medicare (another code or method is used).

Details

Short description
Ht inj palivizumab/ab diem
Date added
01/01/2003
Action effective
04/01/2023
BETOS
Z2

Related S95xx codes

Common questions about S9562

Is HCPCS S9562 still valid?

Yes. S9562 is active in the CMS October 2026 HCPCS file.

Does Medicare cover S9562?

Its coverage code is "I": it is not payable by Medicare (another code or method is used). Check the local coverage determination for your region.